Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

6/28/2021

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

ORION CORPORATION
STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
28 JUNE 2021 at 08.45 EEST

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds increased on 24 June 2021 above five (5) per cent of Orion Corporation's total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

	% of shares and voting rights (total of point A)	% of shares and voting rights through financial instruments (total of point B)	Total of both in % (points A + B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	5.00% shares Below 5% voting rights	0.07% shares Below 5% voting rights	5.07% shares Below 5% voting rights	141,134,278 shares 806,883,011 voting rights
Position of previous notification (if applicable)	4.94% shares Below 5% voting rights	0.07% shares Below 5% voting rights	5.01% shares Below 5% voting rights

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares ISIN code	Number of shares and voting rights		% of shares and voting rights
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI0009014377		7,065,217 shares Below 5% voting rights		5.00% shares Below 5% voting rights
POINT A SUBTOTAL	7,065,217 shares Below 5% voting rights		5.00% shares Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrument	Expiration date	Exercise / Conversion Period	Physical or cash settlement	Number of shares and voting rights	% of shares and voting rights
Securities Lent	N/A	N/A	Physical	66,597 shares Below 5% voting rights	0.04% shares Below 5% voting rights
CFD	N/A	N/A	Cash	35,285 shares Below 5% voting rights	0.02% shares Below 5% voting rights
			POINT B SUBTOTAL	101,882 shares Below 5% voting rights	0.07% shares Below 5% voting rights

Orion Corporation

Timo Lappalainen President and CEO

Olli Huotari SVP, Corporate Functions

Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. [phone]

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

ORION CORPORATION

STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER ANNOUNCEMENTS
28 JUNE 2021 at 08.40 EEST

Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)

Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly or indirectly by BlackRock, Inc. and its funds increased on 24 June 2021 above five (5) per cent of Orion Corporation's total shares.

Total positions of BlackRock, Inc. and its funds subject to notification:

	% of shares and voting rights (total of point A)	% of shares and voting rights through financial instruments (total of point B)	Total of both in % (points A + B)	Total number of shares and voting rights of issuer
Resulting situation on the date on which threshold was crossed or reached	5.00% shares Below 5% voting rights	0.07% shares Below 5% voting rights	5.07% shares Below 5% voting rights	141,134,278 shares 806,883,011 voting rights
Position of previous notification (if applicable)	4.94% shares Below 5% voting rights	0.07% shares Below 5% voting rights	5.01% shares Below 5% voting rights

Notified details of the resulting situation on the date on which the threshold was crossed:

Point A: Shares and voting rights:

Class/type of shares ISIN code	Number of shares and voting rights		% of shares and voting rights
	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)	Direct (SMA 9:5)	Indirect (SMA 9:6 and 9:7)
FI0009014377		7,065,217 shares Below 5% voting rights		5.00% shares Below 5% voting rights
POINT A SUBTOTAL	7,065,217 shares Below 5% voting rights		5.00% shares Below 5% voting rights

Point B: Financial instruments according to SMA 9:6a:

Type of financial instrument	Expiration date	Exercise / Conversion Period	Physical or cash settlement	Number of shares and voting rights	% of shares and voting rights
Securities Lent	N/A	N/A	Physical	66,597 shares Below 5% voting rights	0.04% shares Below 5% voting rights
CFD	N/A	N/A	Cash	35,285 shares Below 5% voting rights	0.02% shares Below 5% voting rights
			POINT B SUBTOTAL	0.07% shares Below 5% voting rights

Orion Corporation

Timo Lappalainen President and CEO

Olli Huotari SVP, Corporate Functions

Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. [phone]

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.